{"SPADE_N_13574": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_N_13574", "Peptide Name": "Humimycin A (human microbiome mycin A, natural AMPs; lipopeptide; nonribosomal peptide; XXL; XXD2; microbiome, bacteria, prokaryotes; UCLL1c)", "Source": "human microbiota", "Family": "Not found", "Gene": "Not found", "Sequence": "YSYFTVV", "Sequence Length": 7, "UniProt Entry": "Ref", "Protein Existence": "Not found", "Biological Activity": ["Anti-Gram+", "Antifungal", "Anti-MRSA"], "Target Organism": "Not found", "Hemolytic Activity": "Not found", "Cytotoxicity": "Not found", "Binding Target": "Not found", "Linear/Cyclic": "Not found", "N-terminal Modification": "Not found", "C-terminal Modification": "Not found", "Stereochemistry": "Not found", "Structure Description": "Not found", "Formula": "Not found", "Mass": 877.98, "PI": 5.52, "Hydrophobicity": 1.01, "Half Life": "Not found", "Function": "Not found", "Literature": [{"Author": "Chu J, Vila-Farres X, Inoyama D, Ternei M, Cohen LJ, Gordon EA, Reddy BV, Charlop-Powers Z, Zebroski HA, Gallardo-Macias R, Jaskowski M, Satish S, Park S, Perlin DS, Freundlich JS, Brady SF. 2016", "Reference": "Nat Chem Biol . 2016 Dec;12(12):1004-1006. doi: 10.1038/nchembio.2207.PubMed", "Title": "Discovery of MRSA active antibiotics using primary sequence from the human microbiome"}], "Frequent Amino Acids": "VYF", "Absent Amino Acids": "ACDEGHIKLMNOPQRUW", "Basic Residues": 0, "Acidic Residues": 0, "Hydrophobic Residues": 5, "Polar Residues": 6, "Positive Residues": 0, "Negative Residues": 0, "Net Charge": 0, "Comments": "APD analysis reveals that the sequence of this peptide shows 41.7% similarity toCn-AMP2.Chemical modification: Y3, T5 are D-amino acids. The N-terminus of the peptide is acylated with a C14 carbon fatty acid with hydroxylation at gamma carbon.Activity: Active against R. mucilaginosa (MIC 8 ug/ml), R. dentocariosa (MIC 16 ug/ml), Eubacterium spp. 3_1_31 (MIC 32 ug/ml), S. aureus MRSA (MIC 8 ug/ml), S. epidermidis (MIC 16 ug/ml), S. mitis (MIC 8 ug/ml), S. mutans (MIC 8 ug/ml), S. delphini (MIC 4 ug/ml), S. intermedius (MIC 8 ug/ml), S. pseudintermedius (MIC 4 ug/ml), S. pneumoniae (MIC 4 ug/ml), and S. sanguinis (MIC 16 ug/ml).Animal model:mouse: It  inhibits lipid II flippase and potentiate beta-lactam activity against MRSA in mice. The original synthetic peptide has been replaced. 9/2020; 7/2021; 4/2024", "Similar Sequences": [{"SPADE_ID": "SPADE_N_05940", "Similarity": 1.0, "Sequence": "AFTCHCRRSCYSTEYSY"}, {"SPADE_ID": "SPADE_N_05944", "Similarity": 1.0, "Sequence": "TCHCRRSCYSTEYSY"}, {"SPADE_ID": "SPADE_N_05953", "Similarity": 1.0, "Sequence": "RSCYSTEYSY"}]}}}